Evidence map›Paper›PMID 31704880›Full record

ArticleJournal of immunology (Baltimore, Md. : 1950)2019

Immune-Focusing Properties of Virus-like Particles Improve Protective IgA Responses.

Taishi Onodera, Kana Hashi, Rajni Kant Shukla, Motohiro Miki, Reiko Takai-Todaka, Akira Fujimoto, Masayuki Kuraoka, Tatsuya Miyoshi, Kazuo Kobayashi, Hideki Hasegawa and 4 more

Open access · bronzeAbstract read
In one paragraph

Article in Journal of immunology (Baltimore, Md. : 1950), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 3 countries.

Taishi OnoderaDepartment of Immunology, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
Kana HashiDepartment of Immunology, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.ORCID 0000-0003-4100-457X
Rajni Kant ShuklaDepartment of Immunology, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.ORCID 0000-0002-5722-449X
Motohiro MikiLaboratory of Viral Infection I, Department of Infection Control and Immunology, Kitasato Institute for Life Sciences, Kitasato University, Tokyo 108-8641, Japan.
Reiko Takai-TodakaLaboratory of Viral Infection I, Department of Infection Control and Immunology, Kitasato Institute for Life Sciences, Kitasato University, Tokyo 108-8641, Japan.
Akira FujimotoLaboratory of Viral Infection I, Department of Infection Control and Immunology, Kitasato Institute for Life Sciences, Kitasato University, Tokyo 108-8641, Japan.
Masayuki KuraokaDepartment of Immunology and Human Vaccine Institute, Duke University, Durham, NC 27710.
Tatsuya MiyoshiSakai City Institute of Public Health, Osaka 590-0953, Japan.ORCID 0000-0003-2469-9672
Kazuo KobayashiDivision of Public Health, Osaka Institute of Public Health, Osaka 537-0025, Japan.ORCID 0000-0002-9249-4030
Hideki HasegawaDepartment of Pathology, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
Manabu AtoDepartment of Immunology, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.ORCID 0000-0002-3178-2645
Garnett KelsoeDepartment of Immunology and Human Vaccine Institute, Duke University, Durham, NC 27710.ORCID 0000-0002-8770-040X
Kazuhiko KatayamaLaboratory of Viral Infection I, Department of Infection Control and Immunology, Kitasato Institute for Life Sciences, Kitasato University, Tokyo 108-8641, Japan.ORCID 0000-0002-7692-1151
Yoshimasa TakahashiDepartment of Immunology, National Institute of Infectious Diseases, Tokyo 162-8640, Japan; ytakahas@niid.go.jp.
National Institute of Infectious Diseases · JPKitasato Institute Hospital · JPDuke University · USInstitute of Public Health · ALDenka (Japan) · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Virus-like particles (VLPs) provide a well-established vaccine platform; however, the immunogenic properties acquired by VLP structure remain poorly understood. In this study, we showed that systemic vaccination with norovirus VLP recalls human IgA responses at higher magnitudes than IgG responses under a humanized mouse model that was established by introducing human PBMCs in severely immunodeficient mice. The recall responses elicited by VLP vaccines depended on VLP structure and the disruption of VLP attenuated recall responses, with a more profound reduction being observed in IgA responses. The IgA-focusing property was also conserved in a murine norovirus-primed model under which murine IgA responses were recalled in a manner dependent on VLP structure. Importantly, the VLP-driven IgA response preferentially targeted virus-neutralizing epitopes located in the receptor-binding domain. Consequently, VLP-driven IgA responses were qualitatively superior to IgG responses in terms of the virus-neutralizing activity in vitro. Furthermore, the IgA in mucosa obtained remarkable protective function toward orally administrated virus in vivo. Thus, our results indicate the immune-focusing properties of the VLP vaccine that improve the quality/quantity of mucosal IgA responses, a finding with important implications for developing mucosal vaccines.

Indexed as

AnimalsAntibodies, ViralAntibody FormationB-LymphocytesCaliciviridae InfectionsHumansImmunity, MucosalImmunoglobulin AImmunoglobulin Class SwitchingImmunoglobulin GImmunologic MemoryMiceMice, TransgenicNorovirusVaccines, Virus-Like ParticleAntibodies, ViralImmunoglobulin AImmunoglobulin GVaccines, Virus-Like Particle

Identifiers

PMID31704880
PMCPMC6900486
OpenAlexW2983035180

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.